1. Medtech Insight
  2. >>Business

Tornier Toes FTC Line With Lower-Extremity Sale To Integra

Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic toe replacement products for an undisclosed cash payment. The deal is intended to satisfy antitrust concerns in Wright Medical's pending purchase of Tornier and to strengthen Integra's position in the lower-extremity market.

Tornier NV has cleared the way to be purchased by Wright Medical Group NV and Integra LifeSciences Holdings Corp. has strengthened its position in the lower-extremity space in a deal announced Sept. 3.

Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Abbott Lowers Outlook But Headwinds Are Temporary

 
• By Natasha Barrow

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

J&J Bets On Robotics, Cardiovascular To Grow Medtech As Tariff Hit Eases, US Manufacturing Grows

 
• By Shubham Singh

Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 
• By Natasha Barrow

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.